Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(39)
•••
Post by TheRessurectionon Jan 03, 2020 6:50pm
41 Views
Post# 30517036

WHOM CHOOSES TO BE AS INTELLIGENT AS ME ???

WHOM CHOOSES TO BE AS INTELLIGENT AS ME ???
 
Given my  Highrider2 banned past, I reckon everybody knows by now how great I think I am given how much time I waste posting lies like a broken record "Pumptard" on the bullboards ...  as per usual ...  LOL  !!! 
 
A good example of my lies was posted on ( on Dec 27th ) when I lied about buying 1.8 million shares of ALEF...  after taking a huge unrecoverable CHV loss.   !!!  One of many examples that I choose to embarrassingly boast about repeatedly ....  amongst many others ... Reality  !!!  LOL !!! We all get to choose !!! 
 
But nonetheless I am once again back posting shamelessly like a uneducated rookie demanding proof of buys from fellow members like to yourself ...  determined to achieve a higher "ignore" achievement count than my previous record setting "1000." 
 
Whoooeeeee .... You gotta luv it !!!! I just can't stop myself ....whooooeeee !!!
 
Time will tell .... LOL ... as per usual !!!
 
 
...  LOL  !!!  Whooooeeeee ... Look at me go !!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities